Taysha Gene Therapies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Taysha Gene TherapiesDer Gewinn des Unternehmens wird voraussichtlich um 0.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 57.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 0.7% pro Jahr wachsen.

Wichtige Informationen

-0.4%

Wachstumsrate der Gewinne

0.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	57.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:TSHA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	37	-80	-115	N/A	6
12/31/2025	5	-97	-65	-76	11
12/31/2024	8	-92	-82	-59	12
9/30/2024	10	-23	-79	-79	N/A
6/30/2024	13	-114	-79	-75	N/A
3/31/2024	14	-118	-76	-73	N/A
12/31/2023	15	-112	-80	-73	N/A
9/30/2023	14	-214	-52	-42	N/A
6/30/2023	10	-124	-62	-53	N/A
3/31/2023	7	-133	-85	-68	N/A
12/31/2022	3	-166	-113	-88	N/A
9/30/2022	N/A	-161	-174	-143	N/A
6/30/2022	N/A	-186	-179	-146	N/A
3/31/2022	N/A	-193	-168	-136	N/A
12/31/2021	N/A	-175	-139	-117	N/A
9/30/2021	N/A	-142	-116	-97	N/A
6/30/2021	N/A	-106	-87	-71	N/A
3/31/2021	N/A	-87	-61	-51	N/A
12/31/2020	N/A	-60	-40	-31	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TSHA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TSHA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TSHA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TSHADie Einnahmen des Unternehmens (57.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: TSHADie Einnahmen des Unternehmens (57.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TSHA in 3 Jahren voraussichtlich hoch sein wird

Taysha Gene Therapies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 25%, EPS upgraded

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

Consensus revenue estimates increase by 40%, EPS downgraded

Consensus estimates of losses per share improve by 33%

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Taysha Gene Therapies, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taysha Gene Therapies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $74.981029 million.

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Taysha Gene Therapies, Inc. Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Taysha Gene Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Taysha Gene Therapies, Inc., Annual General Meeting, May 29, 2024

Consensus revenue estimates increase by 23%

Consensus revenue estimates increase by 25%

Price target increased by 7.9% to US$6.06

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Taysha Gene Therapies, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Taysha: Produces Solid Data But Has Abandoned Programs

Taysha Gene Therapies, Inc. Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Taysha Gene Therapies, Inc. Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

Board Observer recently bought US$163k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Taysha Gene Therapies, Inc. Appoints Alison Long to Board and Committees

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Taysha Gene Therapies, Inc. Announces Second Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

CFO & Corporate Secretary notifies of intention to sell stock

Taysha Gene Therapies, Inc. Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Consensus estimates of losses per share improve by 33%

Taysha Gene Therapies, Inc. announced that it expects to receive $149.952767 million in funding from a group of investors

Taysha Gene Therapies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities

Taysha Gene Therapies, Inc. Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Insider recently sold US$61k worth of stock

New minor risk - Insider selling

Insider recently sold US$308k worth of stock

Taysha Gene Therapies, Inc. Announces First Patient Dosed with Tsha-102 in the Reveal Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Taysha Gene Therapies, Inc., Annual General Meeting, Jun 22, 2023

Taysha Gene Therapies, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 20% to US$5.77

Taysha Gene Therapies, Inc. Provides Update on TSHA-120 Program in Giant Axonal Neuropathy

Price target decreased by 11% to US$14.57

Taysha Gene Therapies, Inc. Announces Separation Suyash Prasad as Chief Medical Officer

Price target decreased to US$15.36

Price target decreased to US$16.79

High number of new and inexperienced directors

Price target decreased to US$17.21

Taysha Gene Therapies, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Taysha Gene Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $28 million.

Price target decreased to US$22.46

Taysha Gene Therapies, Inc. announced that it expects to receive $50 million in funding from Astellas Pharma Inc.

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) dropped from Russell 2000 Growth Index

Chief Technical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Taysha Gene Therapies, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome